Literature DB >> 28833588

Large nose angiosarcoma treated effectively with oral cyclophosphamide combined with propranolol.

J Daguzé1, M Saint-Jean1, B Dréno1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28833588     DOI： 10.1111/jdv.14528

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN： 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  6 in total

Review 1.  Current and Future Directions for Angiosarcoma Therapy.

Authors:  Vaia Florou; Breelyn A Wilky
Journal:  Curr Treat Options Oncol       Date:  2018-03-08

2.  Non-selective beta blockers inhibit angiosarcoma cell viability and increase progression free- and overall-survival in patients diagnosed with metastatic angiosarcoma.

Authors:  Clarissa N Amaya; Mariah Perkins; Andres Belmont; Connie Herrera; Arezo Nasrazadani; Alejandro Vargas; Thuraieh Khayou; Alexa Montoya; Yessenia Ballou; Dana Galvan; Alexandria Rivas; Steven Rains; Luv Patel; Vanessa Ortega; Christopher Lopez; William Chow; Erin B Dickerson; Brad A Bryan
Journal:  Oncoscience       Date:  2018-04-29

3.  Regression of primary cardiac angiosarcoma and metastatic nodules following propranolol as a single agent treatment.

Authors:  Dana C Galván; Anoop P Ayyappan; Brad A Bryan
Journal:  Oncoscience       Date:  2018-10-11

Review 4.  Propranolol for the treatment of vascular sarcomas.

Authors:  Michael J Wagner; Lee D Cranmer; Elizabeth T Loggers; Seth M Pollack
Journal:  J Exp Pharmacol       Date:  2018-09-06

5.  Beta-adrenergic receptor blockade in angiosarcoma: Which beta-blocker to choose?

Authors:  Alaa Embaby; Lisanne van Merendonk; Neeltje Steeghs; Jos Beijnen; Alwin Huitema
Journal:  Front Oncol       Date:  2022-09-15       Impact factor: 5.738

6.  PropAngio study protocol: a neoadjuvant trial on the efficacy of propranolol monotherapy in cutaneous angiosarcoma-a proof of principle study.

Authors:  Kimberley M Heinhuis; Nikki S IJzerman; Anne Miek Koenen; Winette T A van der Graaf; Rick L Haas; Jos H Beijnen; Alwin D R Huitema; Winan J van Houdt; Neeltje Steeghs
Journal:  BMJ Open       Date:  2020-09-10       Impact factor: 2.692
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.